› Forums › General Melanoma Community › Update & pan-RAF?
- This topic has 6 replies, 2 voices, and was last updated 10 years, 3 months ago by NYKaren.
- Post
-
- January 30, 2014 at 4:24 pm
As some of you know, I'm on Tafinlar for 6 months and Menkist for 1. I thought I was failing again, so I literally ran to Dr. Pavlick's office on Wednesday, and my scalp mets (relatively new) look better on their photo, and even better, my LDH went down considerably. Have MRI scheduled for 2/12. My brain feels ok (no loss of speech, confusion, etc. that have accompanied prior mets.)Dr. P told me about Pan-RAF yesterday, which is in a phase 1 clinical trial. I've been researching it, and found it on clinicaltrials.gov. The # is MLN2480.Supposedly it's for use in BRAF+ people…I THINK they either use it alone or might take away the Menkist and add the Pan-RAF drug. I also think it's for MEK resistance???I said to her "well, what happens if I fail with BRAF/MEK and PD1 is still not approved; will I miss out on this trial like I did at Sloan with PD1 phase1?" She said no, she thinks this will be around for a while.anyone know anything about it? Jerry??BTW, I heard PD1 Q3 2014. Fingers crossed!Karen
- Replies
-
-
- January 30, 2014 at 8:36 pm
"Pan-RAF" inhibitors are a new class of drugs intended to inhibit more than one protein involved in tumor cell proliferation. Takeda Pharmaceuticals has invented or purchased two such drugs named "MLN2480" and "TAK-632" which could be used for a number of different types of cancer. They are both in Phase 1 clinical trials.
You can read more about them at: http://meetinglibrary.asco.org/content/114757-132
The MLN2480 clinical trial is NTC01425008
-
- January 30, 2014 at 8:36 pm
"Pan-RAF" inhibitors are a new class of drugs intended to inhibit more than one protein involved in tumor cell proliferation. Takeda Pharmaceuticals has invented or purchased two such drugs named "MLN2480" and "TAK-632" which could be used for a number of different types of cancer. They are both in Phase 1 clinical trials.
You can read more about them at: http://meetinglibrary.asco.org/content/114757-132
The MLN2480 clinical trial is NTC01425008
-
- January 30, 2014 at 8:36 pm
"Pan-RAF" inhibitors are a new class of drugs intended to inhibit more than one protein involved in tumor cell proliferation. Takeda Pharmaceuticals has invented or purchased two such drugs named "MLN2480" and "TAK-632" which could be used for a number of different types of cancer. They are both in Phase 1 clinical trials.
You can read more about them at: http://meetinglibrary.asco.org/content/114757-132
The MLN2480 clinical trial is NTC01425008
-
- You must be logged in to reply to this topic.